<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| INF-8                     | There was significant disagreement among the panel members regarding the addition of the zoster vaccine in this setting. Zoster vaccine was added as a category 3 recommendation with the following statements:  
  • Recommended Timing After HCT: "May be considered at ≥24 mo (if no GVHD or ongoing immunosuppression)"  
  • Footnote "ll": "Because of insufficient data on safety and efficacy of zoster vaccine among HCT recipients, physicians should assess the immune status of each recipient on a case-by-case basis and determine the risk for infection before using the vaccine" | YES 7  
NO 13  
ABSTAIN 0  
ABSENT 4 |